MedTrace Logo

University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

NCT04437290 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-11-02

No results posted yet for this study

Summary

This is a cross-sectional, observational study that characterizes research participants with Alzheimer's disease (AD) for their patterns of brain degeneration with the investigational tau positron emission tomography (PET) radiotracer \[18F\] MK-6240. The goal is to describe the topographic pattern of involvement of cerebral brain regions (topographic phenotyping) in early stage AD participants using tau PET in a sub-cohort of the University of Washington Alzheimer's Disease Research Center (ADRC) Clinical Cohort, and to make this phenotype information available to affiliated research studies at the University of Washington and to the general scientific community via the National Alzheimer's Coordinating Center.

Conditions

  • Alzheimer Disease

Interventions

DRUG

investigational radiotracer [18F]MK6240

Brain PET scan

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Ellison Foundation

    collaborator UNKNOWN

  • University of Washington

    lead OTHER

Principal Investigators

  • Thomas J Grabowski, MD · University of Washington

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2025-04-30
Completion
2025-04-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04437290 on ClinicalTrials.gov